The Executive Summary of this Treatment Improvement Protocol provides an overview on the use of the three Food and Drug Administration-approved medications used to treat opioid use disorder—methadone, naltrexone, and buprenorphine—and the other strategies and services needed to support recovery.
Dashboard: Filter Bricks
Main page content
This Treatment Improvement Protocol (TIP) reviews the use of the three Food and Drug Administration (FDA)-approved medications used to treat OUD—methadone, naltrexone, and buprenorphine—and the other strategies and services needed to support recovery for people with OUD. This is a revision.
This manual offers guidelines for working with suicidal adults living with substance use disorders. It covers risk factors and warning signs for suicide, core competencies, and clinical vignettes. Access the literature review.
This manual provides clinical practice guidelines for using medications in the medication-assisted treatment of alcohol use disorder. It offers guidance on prescribing acamprosate, disulfiram, oral naltrexone, and extended-release injectable naltrexone. The manual also discusses patient management. Access the literature review.
This guide helps substance use counselors treat clients with symptoms of depression and substance use conditions. Program administrators will learn how to integrate depression treatment into early drug treatment. The guidelines cover screening, assessment, treatment, counseling, cultural competence, and continuing care.